Evidence map›Paper›PMID 33933186›Full record

ReviewThe Lancet. Neurology2021

Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group.

Bruno Dubois, Nicolas Villain, Giovanni B Frisoni, Gil D Rabinovici, Marwan Sabbagh, Stefano Cappa, Alexandre Bejanin, Stéphanie Bombois, Stéphane Epelbaum, Marc Teichmann and 10 more

Registry-linked trialOpen access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Lancet. Neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06321588 (Autoimmune Dementia), which is not on this map. Cited by 562 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
562citing papers in PubMed, 10 pooled it
101.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06321588 recruitingnot on this mapstarted 2023, after this paper: background citation

Autoimmune Dementia: Predictors of Neuronal Synaptic Antibodies in Patients With New-ONset Cognitive Impairment and Their Relevance in Non-encephalitic formS: The ADONIS Study

TypeobservationalSponsorAzienda Usl di BolognaRan2023 to 2026Enrolled300ConditionsCognitive Impairment, Dementia
3 · Its place in the literature

Who cites it

562 citing papers in PubMed, 10 syntheses or guidelines pooled it, 973 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Review
  14. Plasma eMTBR-tau243 as a disease biomarker across Alzheimer's disease clinical phenotypes.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

502 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 16 institutions in 7 countries.

Bruno DuboisAssistance Publique-Hôpitaux de Paris (AP-HP) Department of Neurology, Sorbonne University, Paris, France; Institut du Cerveau, Sorbonne University, Paris, France. Electronic address: bruno.dubois@aphp.fr.
Nicolas VillainAssistance Publique-Hôpitaux de Paris (AP-HP) Department of Neurology, Sorbonne University, Paris, France; Institut du Cerveau, Sorbonne University, Paris, France.
Giovanni B FrisoniLaboratory of Neuroimaging of Aging (LANVIE), University of Geneva, Geneva, Switzerland; Memory Clinic, University Hospital of Geneva, Geneva, Switzerland; Laboratory of Alzheimer's Neuroimaging and Epidemiology (LANE), Saint John of God Clinical Research Centre, Brescia, Italy.
Gil D RabinoviciMemory and Aging Center, Department of Neurology and Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA.
Marwan SabbaghCleveland Clinic, Lou Ruvo Center for Brain Health, Las Vegas, NV, USA.
Stefano CappaUniversity School for Advanced Studies, Pavia, Italy; RCCS Mondino Foundation, Pavia, Italy.
Alexandre BejaninSant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Barcelona, Spain; Biomedical Research Institute, Hospital de la Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Barcelona, Spain; Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Madrid, Spain.
Stéphanie BomboisAssistance Publique-Hôpitaux de Paris (AP-HP) Department of Neurology, Sorbonne University, Paris, France; INSERM, CHU Lille, U1171 - Degenerative and vascular cognitive disorders, University of Lille, Lille, France.
Stéphane EpelbaumAssistance Publique-Hôpitaux de Paris (AP-HP) Department of Neurology, Sorbonne University, Paris, France; Inria ARAMIS project team, Inria-APHP collaboratio, Sorbonne University, Paris, France; Institut du Cerveau, Sorbonne University, Paris, France.
Marc TeichmannAssistance Publique-Hôpitaux de Paris (AP-HP) Department of Neurology, Sorbonne University, Paris, France.
Marie-Odile HabertAP-HP Department of Nuclear Medicine, Sorbonne University, Paris, France; CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, Sorbonne University, Paris, France; Institut du Cerveau, Sorbonne University, Paris, France.
Agneta NordbergDepartment of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Karolinska Institute, Stockholm, Sweden; Theme Aging, The Aging Brain, Karolinska University Hospital, Stockholm, Sweden.
Kaj BlennowInstitute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
Douglas GalaskoDepartment of Neurosciences, University of California San Diego, La Jolla, CA, USA.
Yaakov SternCognitive Neuroscience Division, Department of Neurology, Columbia University, New York, NY, USA.
Christopher C RoweDepartment of Molecular Imaging and Therapy, Austin Health, The University of Melbourne, Melbourne, VIC, Australia.
Stephen SallowayDepartment of Neurology and Department of Psychiatry, Alpert Medical School of Brown University, Providence, RI, USA; Butler Hospital, Providence, RI, USA.
Lon S SchneiderKeck School of Medicine of the University of Southern California, Los Angeles, USA.
Jeffrey L CummingsCleveland Clinic, Lou Ruvo Center for Brain Health, Las Vegas, NV, USA; Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas, Las Vegas, NV, USA.
Howard H FeldmanDepartment of Neurosciences, University of California San Diego, La Jolla, CA, USA; Shiley-Marcos Alzheimer's Disease Research Center, University of California San Diego, La Jolla, CA, USA; Alzheimer Disease Cooperative Study, University of California San Diego, La Jolla, CA, USA.
Sorbonne Université · FRCleveland Clinic · USUniversity of California San Diego · USCentre National de la Recherche Scientifique · FRColumbia University · USInserm · FRInstitut national de recherche en sciences et technologies du numérique · FRKarolinska University Hospital · SEProvidence College · USSahlgrenska University Hospital · SEThe University of Melbourne · AUUniversitat Autònoma de Barcelona · ESUniversity of California, San Francisco · USUniversity of Geneva · CHUniversity of Pavia · ITUniversity of Southern California · US

Funding

Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's DiseaseR01AG053798 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI AISEN, PAUL S., CUMMINGS, JEFFREY L. · 2017 to 2022
$39.4M
Research Education ComponentP30AG019610 · NIA · SUN HEALTH RESEARCH INSTITUTE · PI REIMAN, ERIC MICHAEL · 2001 to 2020
$32.5M
USCADRC Diversity Supplement PachicanoP30AG066530 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HELENA Chang CHUI, ARTHUR W TOGA · 2020 to 2026
$27.8M
The Aging Brain: Vasculature, Ischemia, and BehaviorP01AG012435 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI VINTERS, HARRY V. · 1994 to 2012
$26.4M
Research Education ComponentP30AG072980 · NIA · BANNER HEALTH · PI Nicholas Ashton · 2021 to 2026
$24.9M
Renewal of Centers of Biomedical Research Excellence (COBRE) (Phase 2) CNTN - ResubmissionP20GM109025 · NIGMS · CLEVELAND CLINIC FOUNDATION · PI JESSICA KIRKLAND CALDWELL · 2015 to 2026
$22.8M
Chronic Traumatic Encephalopathy: Detection, Diagnosis, Course, and Risk FactorsU01NS093334 · NINDS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI CUMMINGS, JEFFREY L., REIMAN, ERIC MICHAEL · 2016 to 2022
$17.0M
NVEDARC Clinical CoreP20AG068053 · NIA · CLEVELAND CLINIC FOUNDATION · PI FOX, ROBERT J. · 2020 to 2022
$3.3M
NIA NIH HHS P01 AG012435NIA NIH HHS P20 AG068053NIA NIH HHS P30 AG019610NIA NIH HHS P30 AG066530NIA NIH HHS P30 AG072980NIA NIH HHS R01 AG053798NIGMS NIH HHS P20 GM109025NINDS NIH HHS U01 NS093334
6 · The paper itself

Abstract

In 2018, the US National Institute on Aging and the Alzheimer's Association proposed a purely biological definition of Alzheimer's disease that relies on biomarkers. Although the intended use of this framework was for research purposes, it has engendered debate and challenges regarding its use in everyday clinical practice. For instance, cognitively unimpaired individuals can have biomarker evidence of both amyloid β and tau pathology but will often not develop clinical manifestations in their lifetime. Furthermore, a positive Alzheimer's disease pattern of biomarkers can be observed in other brain diseases in which Alzheimer's disease pathology is present as a comorbidity. In this Personal View, the International Working Group presents what we consider to be the current limitations of biomarkers in the diagnosis of Alzheimer's disease and, on the basis of this evidence, we propose recommendations for how biomarkers should and should not be used for diagnosing Alzheimer's disease in a clinical setting. We recommend that Alzheimer's disease diagnosis be restricted to people who have positive biomarkers together with specific Alzheimer's disease phenotypes, whereas biomarker-positive cognitively unimpaired individuals should be considered only at-risk for progression to Alzheimer's disease.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesBiomarkersCognitive DysfunctionDisease ProgressionHumansPhenotypetau ProteinsAmyloid beta-PeptidesBiomarkerstau Proteins

Identifiers

PMID33933186
PMCPMC8339877
OpenAlexW3159530258

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.